PRMT8

Across TCGA pan-cancer cohorts, PRMT8 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRMT8 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRMT8 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRMT8 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM and PDAC are the cancer types where PRMT8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.854	0.600	.005	5	view →
PDAC	DFS	Quartile	II,III,IV	0.986	0.587	.039	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRMT8–GBM (DFS)

Open the GBM breakdown →